NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Publication
, Journal Article
Liu, J; Berchuck, A; Backes, FJ; Cohen, J; Grisham, R; Leath, CA; Martin, L; Matei, D; Miller, DS; Robertson, S; Barroilhet, L; Uppal, S ...
Published in: Journal of the National Comprehensive Cancer Network : JNCCN
October 2024
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Duke Scholars
Published In
Journal of the National Comprehensive Cancer Network : JNCCN
DOI
EISSN
1540-1413
ISSN
1540-1405
Publication Date
October 2024
Volume
22
Issue
8
Start / End Page
512 / 519
Related Subject Headings
- Poly(ADP-ribose) Polymerase Inhibitors
- Peritoneal Neoplasms
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Medical Oncology
- Humans
- Female
- Fallopian Tube Neoplasms
- 4203 Health services and systems
Citation
APA
Chicago
ICMJE
MLA
NLM
Liu, J., Berchuck, A., Backes, F. J., Cohen, J., Grisham, R., Leath, C. A., … Armstrong, D. K. (2024). NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN, 22(8), 512–519. https://doi.org/10.6004/jnccn.2024.0052
Liu, Joyce, Andrew Berchuck, Floor J. Backes, Joshua Cohen, Rachel Grisham, Charles A. Leath, Lainie Martin, et al. “NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.” Journal of the National Comprehensive Cancer Network : JNCCN 22, no. 8 (October 2024): 512–19. https://doi.org/10.6004/jnccn.2024.0052.
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, et al. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN. 2024 Oct;22(8):512–9.
Liu, Joyce, et al. “NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.” Journal of the National Comprehensive Cancer Network : JNCCN, vol. 22, no. 8, Oct. 2024, pp. 512–19. Epmc, doi:10.6004/jnccn.2024.0052.
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen L-M, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN. 2024 Oct;22(8):512–519.
Published In
Journal of the National Comprehensive Cancer Network : JNCCN
DOI
EISSN
1540-1413
ISSN
1540-1405
Publication Date
October 2024
Volume
22
Issue
8
Start / End Page
512 / 519
Related Subject Headings
- Poly(ADP-ribose) Polymerase Inhibitors
- Peritoneal Neoplasms
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Medical Oncology
- Humans
- Female
- Fallopian Tube Neoplasms
- 4203 Health services and systems